Rheumatoid Arthritis Is an Independent Risk Factor for an Increased Augmentation Index Regardless of the Coexistence of Traditional Cardiovascular Risk Factors

2012 ◽  
Vol 42 (1) ◽  
pp. 17-22 ◽  
Author(s):  
Herwig Pieringer ◽  
Tobias Brummaier ◽  
Michael Schmid ◽  
Max Pichler ◽  
Avida Hayat-Khayyati ◽  
...  
Blood ◽  
2017 ◽  
Vol 129 (6) ◽  
pp. 723-728 ◽  
Author(s):  
Robert I. Liem ◽  
Cheeling Chan ◽  
Thanh-Huyen T. Vu ◽  
Myriam Fornage ◽  
Alexis A. Thompson ◽  
...  

Key Points SCT status is not significantly associated with longitudinal changes in fitness among African Americans. SCT status is not an independent risk factor for hypertension, diabetes, or metabolic syndrome among African Americans.


2020 ◽  
Vol 21 (Supplement_1) ◽  
Author(s):  
B Igual Munoz ◽  
E S L C Elena Sanchez Lacuesta ◽  
J L D G Jose Luis Diez Gil ◽  
M F V Maria Ferre Valverdu ◽  
F T M Francisco Ten Morro ◽  
...  

Abstract Intramyocardial hemorrhage (IMH) is considered a marker of tissue damage severity in patients with reperfused ST-segment elevation myocardial infarction (STEMI) and has been associated with a poor prognosis despite successful revascularization of the culprit artery . We aim to study the impact of cardiovascular risk factors and treatment strategies on the presence of IMH studied with T2* -w cardiovascular magnetic resonance (CMR) in this clinical setting METHODS A prospective observational study including patients with repefused STEMI who underwent an MRI during the first week post-revascularization were conducted . The presence of IMH was analyzed in ECG triggered T2 * w sequences as presence of hipointensity area . Clinical data including cardiovascular risk factors and treatment strategies at cath lab were studied. RESULTS 94 patients with reperfused STEMI were included. Demographic data are shown at the the table. No significant association was observed between the presence of IMH and the different treatment strategies used. All data were introduced in a multivariate model including presence of thrombus, total ischemia time and culprit coronary artery. The analysis showed previous infarction as an independent risk factor (OR: 6 p = 0.03, CI: 1.1-29) while history of hypertension (OR: 0.9, p = 0.04, CI: 0.1- 0.9) and systolic blood pressure showed independent protective effect (OR: 0.3 p = 0.02 IC: 0.9-0.99.) CONCLUSIONS. 1. Previous infarction was shown to be an independent risk factor for IMH . 2. Arterial hypertension and systolic blood pressure showed a protective effect. Age (years) 62 ±13 Male sex 72 (77) Diabetes mellitus 32 (34) Hypertension 53 (56) Hyperlipidaemia 52 (55) Current or prior smoking 55 (58) Time to reperfusion 203 (142-300) Infarct-related artery LAD 38 (41) RCA 49 (52) Cx 7 (7) Infarct size (% LV mass) 18 ± 11 MO (% LV mass) 3.15 (1.44-5.48) Abstract P824 Figure. Intramyocardial hemorraghe T2* sequences


2020 ◽  
Vol 79 (11) ◽  
pp. 1400-1413 ◽  
Author(s):  
Philip Mease ◽  
Christina Charles-Schoeman ◽  
Stanley Cohen ◽  
Lara Fallon ◽  
John Woolcott ◽  
...  

ObjectivesTofacitinib is a Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ulcerative colitis, and has been investigated in psoriasis (PsO). Routine pharmacovigilance of an ongoing, open-label, blinded-endpoint, tofacitinib RA trial (Study A3921133; NCT02092467) in patients aged ≥50 years and with ≥1 cardiovascular risk factor identified a higher frequency of pulmonary embolism (PE) and all-cause mortality for patients receiving tofacitinib 10 mg twice daily versus those receiving tumour necrosis factor inhibitors and resulted in identification of a safety signal for tofacitinib. Here, we report the incidence of deep vein thrombosis (DVT), PE, venous thromboembolism (VTE; DVT or PE) and arterial thromboembolism (ATE) from the tofacitinib RA (excluding Study A3921133), PsA and PsO development programmes and observational studies. Data from an ad hoc safety analysis of Study A3921133 are reported separately within.MethodsThis post-hoc analysis used data from separate tofacitinib RA, PsO and PsA programmes. Incidence rates (IRs; patients with events per 100 patient-years’ exposure) were calculated for DVT, PE, VTE and ATE, including for populations stratified by defined baseline cardiovascular or VTE risk factors. Observational data from the US Corrona registries (including cardiovascular risk factor stratification), IBM MarketScan research database and the US FDA Adverse Event Reporting System (FAERS) database were analysed.Results12 410 tofacitinib-treated patients from the development programmes (RA: n=7964; PsO: n=3663; PsA: n=783) were included. IRs (95% CI) of thromboembolic events among the all tofacitinib cohorts’ average tofacitinib 5 mg and 10 mg twice daily treated patients for RA, respectively, were: DVT (0.17 (0.09–0.27) and 0.15 (0.09–0.22)); PE (0.12 (0.06–0.22) and 0.13 (0.08–0.21)); ATE (0.32 (0.22–0.46) and 0.38 (0.28–0.49)). Among PsO patients, IRs were: DVT (0.06 (0.00–0.36) and 0.06 (0.02–0.15)); PE (0.13 (0.02–0.47) and 0.09 (0.04–0.19)); ATE (0.52 (0.22–1.02) and 0.22 (0.13–0.35)). Among PsA patients, IRs were: DVT (0.00 (0.00–0.28) and 0.13 (0.00–0.70)); PE (0.08 (0.00–0.43) and 0.00 (0.00–0.46)); ATE (0.31 (0.08–0.79) and 0.38 (0.08–1.11)). IRs were similar between tofacitinib doses and generally higher in patients with baseline cardiovascular or VTE risk factors. IRs from the overall Corrona populations and in Corrona RA patients (including tofacitinib-naïve/biologic disease-modifying antirheumatic drug-treated and tofacitinib-treated) with baseline cardiovascular risk factors were similar to IRs observed among the corresponding patients in the tofacitinib development programme. No signals of disproportionate reporting of DVT, PE or ATE with tofacitinib were identified in the FAERS database.ConclusionsDVT, PE and ATE IRs in the tofacitinib RA, PsO and PsA programmes were similar across tofacitinib doses, and generally consistent with observational data and published IRs of other treatments. As expected, IRs of thromboembolic events were elevated in patients with versus without baseline cardiovascular or VTE risk factors, and were broadly consistent with those observed in the Study A3921133 ad hoc safety analysis data, although the IR (95% CI) for PE was greater in patients treated with tofacitinib 10 mg twice daily in Study A3921133 (0.54 (0.32–0.87)), versus patients with baseline cardiovascular risk factors treated with tofacitinib 10 mg twice daily in the RA programme (0.24 (0.13–0.41)).


2015 ◽  
Vol 20 (4) ◽  
pp. 327-333 ◽  
Author(s):  
Yi Chun Lai ◽  
Yik Weng Yew

Background: Psoriasis is known to be associated with metabolic syndrome, a well-established risk factor for ischemic heart disease and stroke. Emerging evidence indicates that psoriasis is an independent risk factor for cardiovascular disease and stroke. Objective: To evaluate whether psoriasis is independently associated with myocardial infarction (MI), ischemic heart disease (MI, angina pectoris, or coronary heart disease), and stroke, we conducted a cross-sectional study using the US National Health and Nutrition Examination Survey (NHANES) database. Methods: Data on clinical history of psoriasis, MI, angina pectoris, coronary heart disease, and stroke from the questionnaire as well as laboratory parameters on serum lipid and uric acid levels in the cycle years 2003-2006 and 2009-2012 were analyzed. Multivariate analysis with logistic regression modelling was performed with the aforementioned cardiovascular events or stroke as the dependent variables and with risk factors such as age, gender, ethnic group, current smoking status, alcohol consumption, metabolic syndrome, hyperuricemia, and psoriasis as independent variables. Results: There were 520 cases of psoriasis, and 108 of them had metabolic syndrome (20.8%). Well-established cardiovascular risk factors such as age, gender, ethnic group, smoking, alcohol consumption, metabolic syndrome, and hyperuricemia were also found to have significant associations with MI and ischemic heart disease (all P values <.001). Psoriatic patients were at significantly higher risks of developing MI (odds ratio [OR] 2.24; 95% CI: 1.27-3.95; P = .005) and ischemic heart disease (OR 1.90; 95% CI: 1.18-3.05; P = .008), but not stroke (OR 1.01; 95% CI: 0.48-2.16; P = .744), after adjustment was made for major cardiovascular risk factors. Conclusion: This study provides epidemiological evidence that psoriasis may be independently associated with the development of MI and ischemic heart disease. Physicians should be cognizant of any underlying cardiovascular risk factors, especially among psoriatic patients with metabolic syndrome, and manage them according to national guidelines.


2020 ◽  
Vol 9 ◽  
pp. 204800402095685
Author(s):  
Ara H Rostomian ◽  
Jonathan Soverow ◽  
Daniel R Sanchez

Objectives While several studies have examined the risk of cardiovascular disease (CVD) in larger racial and ethnic groups within the United States, limited information is available on smaller sub-populations, such as Armenians, with high rates of CVD in their home country. This study examined the association between Armenian ethnicity and a positive exercise treadmill test (ETT). Design Prospective cohort study of patients at a 377-bed county hospital in Los Angeles, California from 2008–2011. Setting All patients were interviewed at the time of ETT to assess their cardiovascular risk factors at the cardiac laboratory of the hospital. Participants 5,006 patients between 18–89 years of age, of whom 12.6% were of Armenian ethnicity and 54.4% were female. Main Outcome Measure: ETT results as a proxy for CVD risk. Results After adjusting for cardiovascular risk factors, Armenian ethnicity was significantly associated with higher odds of positive ETT (OR = 1.40, p = 0.01). Known coronary artery disease CAD (OR = 2.28, p < 0.01), hyperlipidemia (OR = 1.37, p < 0.01), and hypertension (OR = 1.24, p = 0.05) were significantly associated with higher odds of a positive ETT. In subgroup analyses, hyperlipidemia was the only significant predictor of positive ETT (OR = 1.92, p = 0.02) among Armenians, while patient history of CAD (OR = 2.49, p < 0.01), hyperlipidemia (OR = 1.29, p = 0.03), and age (OR = 1.04, p < 0.01) were significant predictors among non-Armenians. Armenian ethnicity remained associated with higher odds of positive ETT (OR = 1.40, p < 0.01) when patients with CAD were excluded. Conclusion Armenian ethnicity may be an independent risk factor for CVD, influenced by the uniformity of the genetic pool and cultural and dietary exposures.


2012 ◽  
Vol 1 (1) ◽  
pp. 1-8
Author(s):  
Dilli Ram Kafle

Patients with diabetes mellitus have 2 to 4 times increased risk for cardiovascular disease than non-diabetic patients. However this excess risk is not fully explained by the traditional cardiovascular risk factors (Hypertension, Hypercholesterolaemia, Smoking and Obesity) which are also associated with diabetes. Fibrinogen has been identified as an independent risk factor for cardiovascular disease and it is associated with traditional cardiovascular risk factors. Studies done in the Caucasians have shown fibrinogen to be higher in diabetic than the non-diabetic patients. Elevated fibrinogen in diabetic patients may be responsible for the increased cardiovascular risk in those patients. Elevated fibrinogen is also associated with increased mortality in general population.DOI: http://dx.doi.org/10.3126/jonmc.v1i1.7281 Journal of Nobel Medical College Vol.1(1) 2011 1-8


2021 ◽  
Vol 30 (4) ◽  
pp. 576-582
Author(s):  
Calin D. Popa

Rheumatoid arthritis (RA) patients have a 1.5 – 2.5 higher chance to develop cardiovascular diseases (CVD), which in turn represent the most important cause of mortality and the most frequent comorbidity in these patients. Chronic inflammation crucially contributes to that, either as an independent risk factor or as a modulator of traditional cardiovascular (CV) risk factors, such as dyslipidemia and hypertension. The cardiovascular risk management (CVRM) is therefore essential in these patients. The implementation of it in the daily practice is quite challenging and requires a good networking between different specialists (rheumatologist, cardiologist, internist) and the general practitioners (GPs), and may get various forms of organization depending on region and locations.


Author(s):  
Anh Binh Ho

Đặt vấn đề: Tổn thương thận cấp do thuốc cản quang là một trong những biến chứng quan trọng mà nếu dự đoán sớm các YTNC chúng ta có biện pháp phòng ngừa. Gần đây các nhà nghiên cứu còn đề xuất ra nhiều bảng điểm để xác định nguy cơ xuất hiện tổn thương thận cấp do thuốc cản quang như: điểm nguy cơ Mehran tỉ số giữa lượng thuốc cản quang và mức lọc cầu thận ước đoán. Chúng tôi nghiên cứu đề tài với mục tiêu: Đánh giá mối liên quan giữa các yếu tố nguy cơ tim mạch, điểm Mehran với tổn thương thận cấp do thuốc cản quang Đối tượng: 221 BN bệnh động mạch vành có chỉ định chụp, can thiệp động mạch vành. Phương pháp nghiên cứu: Mô tả cắt ngang, tiến cứu. Kết quả: Hạ huyết áp quanh thủ thuật là YTNC độc lập của tổn thương thận cấp do thuốc cản quang với OR = 5,299, khoảng tin cậy 95% 1,177-23,854 và P = 0,030. Nồng độ NT-proBNP là YTNC độc lập của tổn thương thận cấp do thuốc cản quang với OR = 1,000, khoảng tin cậy 95% 1,000-1,000 và P = 0,018. Điểm nguy cơ Mehran ở nhóm nguy cơ cao (11-15 điểm) là YTNC độc lập của tổn thương thận cấp do thuốc cản quang với OR = 7,983, khoảng tin cậy 95% 1,080-58,990 và P = 0,042. Điểm nguy cơ Mehran ở nhóm nguy cơ rất cao (≥ 16 điểm) là YTNC độc lập của tổn thương thận cấp do thuốc cản quang với OR = 53,821, khoảng tin cậy 95% 3,046-951,033 và P = 0,007. Kết luận: Hạ huyết áp quanh thủ thuật, nồng độ NT-proBNP, điểm Mehran ở nhóm nguy cơ cao và rất cao là YTNC độc lập của tổn thương thận cấp do thuốc cản quang. Từ khóa: Điểm nguy cơ Mehran, tổn thương thận cấp, thuốc cản quang, động mạch vành. ABSTRACT STUDY OF RELATIONSHIP BETWEEN CARDIOVASCULAR RISK FACTORS, MEHRAN SCORE AND CONTRAST - ASSOCIATED ACUTE KIDNEY INJURY Background: Contrast - associated acute kidney injury which is one of the major complications of percutaneous coronary intervention (PCI) can be prevented if it is predicted through risk factors. In recent years, researchers suggest many risk scores to determine the risk of contrast - induced acute kidney injury such as: Mehran risk score, the ratio between the amount of contrast, and estimated GFR. So we implement the study to find out the relationship between cardiovascular risk factors and contrast - associated acute kidney injury Objects: 221 patients who were diagnosed with coronary disease and treated by PCI. Methods: Prospective observational study. Results: Hypotension during the procedure is a independent risk factor of contrast-associated acute kidney injury with OR = 5,299, 95%CI 1,177-23,854 (p = 0,030). NT-proBNP is is a independent risk factor of contrast-associated acute kidney injury with OR = 1,000, 95%CI 1,000-1,000 (p = 0,018). Mehran score for the high risk patients (11-15 points) is an independent risk factor of contrast-associated acute kidney injury with OR = 7,983, 95%CI 1,080-58,990 (P = 0,042). Mehran score for the very high risk patients (≥ 16 points) is an independent risk factor of contrast-associated acute kidney injury with OR = 53,821, 95%CI 3,046-951,033 (P = 0,007). Conclusion: Intraoperative hypotension, NT-proBNP, Mehran score in high and very high risk groups are independent risk factors of contrast-associated acute kidney injury.


2020 ◽  
Vol 16 ◽  
Author(s):  
Rahil Taheri ◽  
Shahram Molavynejad ◽  
Parvin Abedi ◽  
Elham Rajaei ◽  
Mohammad Hosein Haghighizadeh

Aim: The aim of this study was to investigate the effect of dietary education on cardiovascular risk factors in patients with rheumatoid arthritis. Method: In this randomized clinical trial, 112 patients with rheumatoid arthritis were randomly assigned into two groups, intervention and control. Dietary education was provided for the intervention group in 4 sessions; anthropometric measurements, serum levels of RF, triglycerides, cholesterol, HDL, LDL, and fasting blood sugar were measured before and three months after intervention. Data was analyzed using SPSS software and appropriate statistical tests. Results: The mean of total cholesterol (p <0.001), triglycerides (p = 0.004), LDL (p <0.001), systolic blood pressure (p = 0.001), diastolic blood pressure (p = 0.003), FBS and BMI (p <0.001) were decreased significantly in the intervention group after education compared the control group. Conclusion: Traditional care for rheumatoid arthritis patients is not enough. Patients need more education in order to improve their situation.


Sign in / Sign up

Export Citation Format

Share Document